The Pharmacy Times® IVIG Resource Center is a comprehensive resource for clinical news and expert insights on the use of intravenous immunoglobulin, a product comprised of antibodies administered intravenously.
July 24th 2024
It is essential for clinicians to properly diagnose patients with suspected AVWS and provide them proper treatment, which could be intravenous immunoglobulin.
Exploring Targeted Treatment Options for Hereditary Angioedema: Considerations for Pharmacists
1.0 Credit / Immunology
View More
Unveiling the Impact of Childhood Eczema: A Guide to Moderate-Severe Pediatric Atopic Dermatitis
1.0 Credit / Dermatology, Immunology
View More
Revolutionizing Pediatric Atopic Dermatitis Treatment With Targeted Biologics
1.0 Credit / Dermatology, Immunology
View More
Practical Approaches in the Management of Primary Immunodeficiency Disorders: Understanding the Role of Intrav...
1.0 Credit / Immunology, Rare Diseases
View More
Maximizing the Potential of Biologics in Moderate to Severe Pediatric Atopic Dermatitis: The Expertise of the ...
1.0 Credit / Dermatology, Immunology
View More
Managed Care Perspectives on the Burden of Food Allergies and Advances in Treatment
1.5 Credits / Allergy, Immunology
View More
Best Practices for Optimizing Biologic Therapy Management for Moderate to Severe Atopic Dermatitis in Children
1.5 Credits / Dermatology, Immunology
View More
Integrating Biologic Therapy Into Clinical Practice for the Management of Eosinophilic Esophagitis
1.5 Credits / Gastroenterology, Immunology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Understanding the Burden of Eosinophilic Esophagitis in Children
1.0 Credit / Gastroenterology, Immunology
View More
Emerging Biologic Therapy for the Management of Eosinophilic Esophagitis in Children
1.0 Credit / Gastroenterology, Immunology
View More
The Expertise of the Specialty Pharmacist in Pediatric Eosinophilic Esophagitis
1.0 Credit / Gastroenterology, Immunology
View More
Optimizing Inflammatory Bowel Disease Treatment: A Pharmacist's Guide to Biologics and Monoclonal Antibodies
1.0 Credits / Gastroenterology, Immunology
View More
Navigating the Complexities of Biologic Therapy for Moderate to Severe Atopic Dermatitis in Children: The Impa...
1.5 Credit / Dermatology, Immunology
View More
Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care
1.5 Credits / Dermatology, Immunology
View More
Emerging Concepts and Approaches in the Treatment of Food Allergy: What Managed Care Professionals Need to Kno...
1.5 Credits / Immunology, Allergy
View More
Strategies for Integrating Biologic Therapy Into the Management of Eosinophilic Esophagitis
1.5 Credits / Immunology, Gastroenterology
View More
Reducing Barriers to the Integration of Biologic Therapy in the Management of Pediatric Moderate to Severe Ast...
1.5 Credits / Immunology
View More
Exploring Innovative Approaches in Myasthenia Gravis and the Specialty Pharmacist’s Role in Optimizing Value-B...
1.5 Credits / Immunology
View More
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
1.0 Credit / Immunology, Neurology
View More
An Overview of Disease Burden Associated With COPD
1.0 Credit / Immunology, Pulmonology
View More
Subcutaneous Immunoglobulin Shows Quality of Life Improvement in Patients With CIDP
August 25th 2021Patients with chronic inflammatory demyelinating polyneuropathy who transitioned from intravenous immune globulin to subcutaneous immune globulin showed significantly improved quality-of-life measures.
Read More
Intravenous Immunoglobulin Offers New Treatment Opportunities for Neurological Diseases
May 10th 2021Although it is currently used off-label for many neuroinflammatory and neurodegenerative disorders, intravenous immunoglobulin is showing promise for a growing number of neurological diseases.
Read More
Duration of Vancomycin Reduced Through Education of Prescribers, Utilization of MRSA PCR Nasal Swab
December 8th 2020The objective of the study was to develop a method for de-escalation of intravenous (IV) vancomycin in patients receiving vancomycin with at least 1 other antibiotic appropriate for the treatment of community-acquired pneumonia (CAP).
Read More